Yuhan's new peptic ulcer drug soon on phase III studies.
Published: 2003-10-06 06:57:00
Updated: 2003-10-06 06:57:00
Yuhan announced that the phase III clinical studies of YH1885 (Revanex: revaprazan) was scheduled to conduct for the duodenal ulcer in Oct. and for the GERD (gastro-esophageal reflux disease) in the end of this year or the early of next year.
The phase II study for the duodenal ulcer was perfo...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
